Discussing GI ASCO 2023 Highlights
Key Points:
- SPOTLIGHT – Zolbetuximab with mFOLFOX6 Meets Primary Endpoint
- NAPOLI3 – Randomized Phase III study of first-line liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma
- Analysis of the impact of eliminating bolus 5-fluorouracil in metastatic colon cancer
- MOUNTAINEER – FDA approval of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer
- SUNLIGHT – Trifluridine/Tipiracil plus Bevacizumab provides benefit in refractory metastatic colorectal cancer
Discussing GI ASCO 2023 Highlights – practice changing/informing studies with Dr. Mark Lewis, a Cancer Survivor, Director of GI Oncology at Intermountain Healthcare.
